Differentially Expressed Blood ARLNC1 in Combination with PCA3/PSA has Reassuring Clinical Applications in the Early Diagnosis of Prostate Cancer in Iranians: A pilot study.
Our findings showed that in the diagnosis of prostate cancer, measuring the expression of PCA3, PSA, and ARLNC1 genes is necessary to determine the health, benign, or cancerous status of patients' prostate. Also, selecting the PCA3/PSA ratio provides a new approach for diagnosing this cancer if confirmed in a larger clinical sample size and functional studies.
Authors
- Farkhondeh Pouresmaeili (ORCID: https://orcid.org/0000-0002-4556-2352)
- Mehdi Azizmohammad Looha (ORCID: https://orcid.org/0000-0002-0700-1431)
- Nasser Simforoosh
- Mahan Mohammadi (ORCID: https://orcid.org/0000-0002-9170-9343)
- Azadeh Arabi
- Bahman Jamali
Institutions
- Atomic Energy Organization of Iran (IR)
- Islamic Azad University of Kermanshah (IR)
- Research Institute for Endocrine Sciences (IR)
- Shahid Beheshti University of Medical Sciences (IR)
Publication Details
- Journal
- PubMed
- Published
- 2025-03-02
- DOI
- https://doi.org/10.22037/uj.v21i.8144
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00